Catalog of Interviews and Bits

Catalog of Interviews and Bits

By kjagradio
Download on the App Store

Catalog of Interviews and Bits episodes

  • FDA Approves First-of-its-Kind Treatment for Metastatic Breast Cancer
    RADIO AND SATELLITE INTERVIEW OPPORTUNITY
    THURSDAY, JUNE 27th, 2019, 7:30-NOON ET
    FDA APPROVES FIRST-OF-ITS-KIND TREATMENT FOR METASTATIC
    BREAST CANCER PATIENTS WITH A SPECIFIC MUTATION
    Breast Cancer Expert and Patient Advocate Discuss Why Mutations Matter for
    Postmenopausal Women, and Men, Living with Metastatic Breast Cancer
    AVAILABLE FOR INTERVIEW
    Dr. Virginia Kaklamani, Professor of Hematology/Oncology at UT Health San Antonio
    Shirley Mertz, President of the Metastatic Breast Cancer Network (MBCN)
    Americans are more aware than ever about genetic testing and mutations in metastatic breast cancer, such as the increased risks associated with the BRCA1/2 gene. What they may not know is that tumors can develop mutations that impact how the breast cancer responds to treatment. Following a recent FDA approval of a new medicine, postmenopausal women and men living with HR+/HER2- metastatic breast cancer who have progressed on or after an endocrine-based regimen may be eligible for treatment if a PIK3CA mutation is detected.
    The FDA recently approved a new medication to treat women who have gone through menopause and men who haveHR+/HER2- advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic). Thisimportant milestone marks the first time physicians are able to test advanced or metastatic breast cancer patients for aspecific mutation and develop a personalized treatment plan.
    Mutations of this kind occur in approximately 40% of HR+/HER2- breast cancers, the most common type of breast cancer. The mutations may lead to tumor growth, cause resistance to endocrine therapies and result in a poor overall prognosis. Dr. Virginia Kaklamani, Professor of Hematology/Oncology at UT Health San Antonio , is available to discuss this newtreatment option for patients.
    Shirley Mertz, President of the Metastatic Breast Cancer Network (MBCN), is also available to share her perspective on the importance for patients of knowing their breast cancer type.
    SUGGESTED INTERVIEW QUESTIONS
    Shirley and Dr. Kaklamani, why is this FDA approval significant?
    Shirley, in your experience as an advocate, how does HR+/HER2- metastatic breast cancer impact the lives of men and postmenopausal women?
    Shirley, what does it mean to have a new treatment option available for patients living with HR+/HER2- metastatic breast cancer with a PIK3CA mutation?
    Dr. Kaklamani, how do PIK3CA mutations affect prognosis and progression in HR+/H
    0 min
  • Richard K 9/19/2019
    About Richard Kuritz:
    Richard Kuritz Is a Political Scientist, Writer, PR Strategist and Carpenter.
    He is an unapologetic New Yorker who transplanted his tribe from the NY tundra to San
    Diego sunshine over three decades ago.
    His background includes securities, finance, construction and elected office.
    Currently, Rich works as a Media Relations Specialist, bringing experts to media around
    the country.
    Richard’s independent perspective on America crosses party lines and is anchored in
    common sense and the Constitution. He resides in the San Diego sunshine with his
    high school sweetheart, his fantastic dog and has too many books-in-progress. His
    commentary is found in columns, national magazines and on radio across the country.
    0 min
  • Adam
    Concerning the recent discovery of vaping related illnesses, Kansas was found to have a 4.6 percent prevalence of e-cigarette smoking. Our analysts wanted to bring awareness to this growing issue (and how this could affect health coverage for users) by compiling Center of Disease Control (CDC) data and found:
    Key findings:
    Kansas is tied with New Hampshire, North Carolina, and Idaho at 24th-highest usage rates in the country.
    States with the highest rate of vapers: Oklahoma (7.1 percent), Kentucky (6.1), Indiana (6.0), Tennessee (5.9), and Wyoming (5.8).
    States with the lowest rate of vapers: California (3.0 percent), Vermont (3.1), Connecticut (3.2), Massachusetts (3.3), and Maryland (3.3).
    3.9 million middle school and high school aged teens currently vape.
    We gathered this timely data because if e-cigarettes are declared as a derivative classification of a tobacco product in the eyes of states and insurers, those folks could see a 50 percent increase in their monthly health insurance premium costs.
    To view the full report, visit https://quotewizard.com/news/posts/states-with-most-vapers
    Let me know if you would like to talk with one of our health care analysts about this vaping data. I would be happy to set that up. I am looking forward to hearing from you and thank you for your time.
    Best regards,
    Nathan Barber | QuoteWizard by LendingTree
    Content Specialist
    11115 Rushmore Drive Charlotte, NC 28277 USA
    0 min

About Catalog of Interviews and Bits

From the publisher's feed

The past interviews and comedy skits and bits along with past air checks and Advertisements, I have made or participated on. Included here for your enjoyment and ridicule.